<DOC>
	<DOCNO>NCT00652938</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish necessary cause cervical cancer . Vaccination pre-teens adolescent , ideally sexual debut thus exposure oncogenic HPV , rational strategy prevention cervical cancer . Thus , HPV vaccination could complement exist pre-adolescent/adolescent vaccination program . This Phase IIIb study design evaluate immunogenicity safety co-administering commercially available vaccine GSK Biologicals ' HPV-16/18 L1 VLP AS04 ( Cervarix TM ) vaccine compare administration either vaccine alone .</brief_summary>
	<brief_title>Evaluation Immunogenicity Safety Human Papillomavirus ( HPV ) Vaccine Co-administered With Another Vaccine Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or parents/legally acceptable representative ( LARs ) comply requirement protocol ( e.g . completion diary card , return followup visit ) enrol study . A female , include , 9 15 year age ( attained 16th birthday ) time first vaccination . Written inform consent obtain subject 's parent/LAR prior enrolment . In addition , write informed assent must obtain subject . Healthy subject establish medical history clinical examination enter study . Subjects must pregnant . Absence pregnancy verify urine pregnancy test . If subject female , must nonchildbearing potential , childbearing potential , must practice adequate contraception least 30 day prior vaccination , negative pregnancy test continue precaution two month completion vaccination series . Subjects reach menarche ( begin menstruate ) study , therefore become childbearing potential , must agree follow precaution . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period ( Month 12 ) . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day dose vaccine . Administration routine vaccine meningococcal , inactivated influenza , diphtheria/tetanus and/or diphtheria/tetanuscontaining vaccine 8 day first dose study vaccine allow . Concurrently participate another clinical study , time study period ( Month 12 telephone contact ) , subject expose investigational noninvestigational product ( pharmaceutical product device ) . A subject planning become pregnant , likely become pregnant ( determined investigator ) planning discontinue contraceptive precaution study period two month last vaccine dose . Pregnant breastfeed woman . Previous vaccination HPV plan administration HPV vaccine foreseen study protocol study period . Previous administration component investigational vaccine . Previous vaccination hepatitis B plan administration hepatitis B vaccine foreseen study protocol study period . History hepatitis B infection . Known exposure hepatitis B within previous 6 week . Known acute chronic , clinically significant neurologic , hepatic renal functional abnormality , determine previous physical examination laboratory test . Cancer autoimmune disease treatment . History allergic disease reaction likely exacerbate component vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period .</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Co-administration</keyword>
	<keyword>HPV vaccine</keyword>
	<keyword>Cervical cancer</keyword>
</DOC>